1.. Introduction {#s0001}
================

Among the bacterial infections which create huge medical problems worldwide, the *Mycobacterium tuberculosis* one is among the most threatening due to a number of causes: (i) it is estimated that one in each three people is latently infected with this pathogen, and although clinical manifestations emerge only in ill, old-aged or immunosuppressed patients, the ease of transmission of this infection creates serious medical challenges[@CIT0001]^,^[@CIT0002]; (ii) a large number of *M. tuberculosis* strains became drug resistant or extensively drug resistant to most of almost all clinically used antimycobacterials[@CIT0001]^,^[@CIT0002]; (iii) no new such drugs were launched for the last 30 years, which coupled to the general antibiotic resistance of many other pathogenic bacteria, of which *M. tuberculosis* is the tip of the iceberg, may lead to the resurgence of fatal bacterial infections worldwide.

In fact, since the 1950s, it has been considered that the fight against infective diseases caused by bacteria has been a success[@CIT0001]^,^[@CIT0002]. However, this does not seem to be the case any longer and new approaches for detecting novel antibacterial drug targets are immediately necessary in order to address this serious medical problem. Proteomics ultimately afforded the possibility to evidence new such drug targets, and among the many proposed proteins are also the bacterial carbonic anhydrases (CAs, EC 4.2.1.1), a family of metalloenzymes involved in crucial steps of the pathogen life cycle[@CIT0003]. In *M. tuberculosis*, three CAs belonging to the β-CA class have been discovered, encoded by the genes Rv1284 (mtCA 1), Rv3588c (mtCA 2) and Rv3273 (mtCA 3)[@CIT0003]. Their inhibition with a variety of compounds such as sulphonamides, phenols and dithiocarbamates (all acting as efficient CA inhibitors)[@CIT0006] was shown to lead to an impaired growth of the pathogen[@CIT0005], allowing us to propose mtCAs as anti-mycobacterial drug targets. Indeed, bacteria encode for CAs belonging to three different genetic families, the α-, β- and γ-CAs[@CIT0006], and their inhibition was recently investigated in some details in the search of antibiotics with a novel mechanism of action[@CIT0006]^,^[@CIT0010]. In fact, CA inhibitors (CAIs) of the sulphonamide or sulphamate type, targeting mammalian (human, h) CAs, are in clinical use as diuretics, antiglaucoma, antiepileptic or antiobesity agents for decades[@CIT0016], whereas more recently their use for the management of hypoxic tumours, neuropathic pain, cerebral ischemia and arthritis started to emerge[@CIT0019]. These diverse applications are due to the fact that at least 15 different α-CA isoforms are present in humans, being involved in critical physiological and pathological processes[@CIT0016].

In contrast to the CAIs, the CA activators (CAAs) were much less investigated[@CIT0022]^,^[@CIT0023]. This type of compounds participates in the CA catalytic cycle, which is shown schematically in the following equations: $$\begin{matrix}
{\text{H}_{\text{2}}\text{O}} \\
\left. \text{EZn}^{\text{2} +} - \text{OH}^{-} + \text{~CO}_{\text{2}}\Leftrightarrow\text{EZn}^{\text{2} +}-\text{HCO}_{\text{3}}^{-}\Leftrightarrow\text{EZn}^{\text{2} +}-\text{OH}_{\text{2}} + \text{HCO}_{\text{3}}^{-} \right. \\
\end{matrix}$$$$\left. \text{EZn}^{\text{2} +}-\text{OH}_{\text{2}}\Leftrightarrow\text{EZn}^{\text{2} +}-\text{HO}^{-} + \text{~H}^{+} \right.$$

The first step involves the nucleophilic attack of a zinc-bound hydroxide species of the enzyme on the CO~2~ substrate, bound in a hydrophobic pocket nearby and optimally orientated for the hydration reaction ([Equation (1)](#M0001){ref-type="disp-formula"})[@CIT0007]^,^[@CIT0008]. Bicarbonate formed in the hydration reaction is then replaced by an incoming water molecule, with the generation of the catalytically acid form of the enzyme, EZn^2+^−OH~2~ ([Equation (1)](#M0001){ref-type="disp-formula"}). For the regeneration of the zinc hydroxide species, a proton transfer reaction occurs from the Zn(II)-bound water molecule to the external medium ([Equation (2)](#M0002){ref-type="disp-formula"}), which is the rate-determining step of the entire catalytic cycle: $$\begin{matrix}
\left. \text{EZn}^{\text{2} +}-\text{OH}_{\text{2}} + \text{A}\Leftrightarrow\lbrack\text{EZn}^{\text{2} +}-\text{OH}_{\text{2}} - \text{A}\rbrack\Leftrightarrow\lbrack\text{EZn}^{\text{2} +}-\text{HO}^{-} - \text{~AH}^{+}\rbrack\Leftrightarrow\text{EZn}^{\text{2} +}-\text{HO}^{-} + \text{AH}^{+} \right. \\
{\text{enzyme~} - \text{~activator~complexes}} \\
\end{matrix}$$

In the presence of activators (A in [Equation (3)](#M0003){ref-type="disp-formula"}), the formation of enzyme--activator complexes occurs, in which the proton transfer reaction became intramolecular, being thus more efficient than the corresponding intermolecular process[@CIT0007]^,^[@CIT0008]. This mechanism of CA activation was demonstrated by kinetic and crystallographic studies for the human isoforms hCA I and II[@CIT0009]. The activator-binding site was shown to be situated at the entrance of the active site cavity. Most of the activators belong to the amino and/or amino acid chemotypes, and possess moieties with an appropriate p*K*a (generally in the range of 6--8) for efficient proton shuttling processes between the active site and the environment[@CIT0007].

CAAs were extensively investigated in the last period for their interaction with all human CAs[@CIT0024], but their effects on bacterial enzymes were poorly studied up until now[@CIT0031]. The same situation is in fact valid for the investigation of bacterial CA inhibitors, ad mentioned above[@CIT0031].

Considering the fact that few CA activation studies of bacterial enzymes are available, and none of them for the mycobacterial enzymes, here we report the first such study in which we evaluated the activation of mtCA 3 (encoded by the gene Rv3273) with a panel of amines and amino acid derivatives.

2.. Materials and methods {#s0002}
=========================

2.1.. Materials {#s0003}
---------------

Amino acids and amines **1--19** were commercially available, highest purity reagents from Sigma-Aldrich, Milan, Italy. Rv3273 was a recombinant protein produced as reported earlier by our group[@CIT0004]^,^[@CIT0005].

2.2.. CA enzyme activation assay {#s0004}
--------------------------------

An Sx.18Mv-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to assay the catalytic activity of various CA isozymes for CO~2~ hydration reaction[@CIT0034]. Phenol red (at a concentration of 0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, with 10 mM Hepes (pH 7.5) or TRIS (pH 8.3) as buffers, 0.1 M Na~2~SO~4~ (for maintaining constant ionic strength), following the CA-catalysed CO~2~ hydration reaction for a period of 10 s at 25 °C. Activity of the α-CAs was measured at pH 7.5 whereas that of the β-class enzymes at pH 8.3 in order to avoid the possibility that their active site is closed[@CIT0003]. The CO~2~ concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and activation constants. For each activator at least six traces of the initial 5--10% of the reaction have been used for determining the initial velocity. The uncatalysed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of activators (10 mM) were prepared in distilled--deionised water and dilutions up to 1 nM were done thereafter with the assay buffer. Activator and enzyme solutions were pre-incubated together for 15 min (standard assay at room temperature) prior to assay, in order to allow for the formation of the E--A complex. The activation constant (K~A~), defined similarly with the inhibition constant K~I~, can be obtained by considering the classical Michaelis--Menten equation ([Equation (4)](#M0004){ref-type="disp-formula"}), which has been fitted by non-linear least squares by using PRISM 3: $$\text{v~} = \text{v}_{\text{max}}/\left\{ {\text{1} + \text{K}_{\text{M}}/\left\lbrack \text{S} \right\rbrack\left( {\text{1} + \left\lbrack \text{A} \right\rbrack_{\text{f}}/\text{K}_{\text{A}}} \right)} \right\}$$ where \[A\]~f~ is the free concentration of activator.

Working at substrate concentrations considerably lower than K~M~ (\[S\] **≪**K~M~), and considering that \[A\]~f~ can be represented in the form of the total concentration of the enzyme (\[E\]~t~) and activator (\[A\]~t~), the obtained competitive steady-state equation for determining the activation constant is given by the following equation: $$\left. \text{v} = \text{v}_{0}.\text{K}_{\text{A}}/\left\{ {\text{K}_{\text{A}} + \left( {\left\lbrack \text{A} \right\rbrack_{\text{t}} - 0.\text{5}\left\{ \left( {\left\lbrack \text{A} \right\rbrack_{\text{t}} + \left\lbrack \text{E} \right\rbrack_{\text{t}} + \text{K}_{\text{A}}} \right) - \left( {\left\lbrack \text{A} \right\rbrack_{\text{t}} + \left\lbrack \text{E} \right\rbrack_{\text{t}} + \text{K}_{\text{A}}} \right)^{\text{2}} - \text{4}\left\lbrack \text{A} \right\rbrack_{\text{t}}.\left\lbrack \text{E} \right\rbrack_{\text{t}} \right.} \right)^{\text{1}/\text{2}}} \right\} \right\}$$ where v~0~ represents the initial velocity of the enzyme-catalysed reaction in the absence of activator[@CIT0023].

3.. Results and discussion {#s0005}
==========================

Natural and non-natural amino acids and amines **1--19** were included among the investigated compounds ([Figure 1](#F0001){ref-type="fig"}). These activators were included in this study, as they were employed for investigations as CAAs against many classes of CAs, including the few bacterial ones investigated so far[@CIT0033].

![Amino acids **1--11** and amines **12--19** investigated as mtCA 3 activators.](IENZ_A_1422250_F0001_B){#F0001}

Data of [Table 1](#t0001){ref-type="table"} show that [l]{.smallcaps}-Trp (at 10 µ.M concentration), which is a medium potency activator for all enzymes considered here, i.e. hCA I, II and mtCA 3, enhanced k~cat~ values for all of them, whereas K~M~ remained unchanged, a situation observed for all CAAs investigated so far, both for those belonging to vertebrates (α-class enzymes) and micro-organism (enzymes belonging to various CA genetic families)[@CIT0023]^,^[@CIT0033]. [l]{.smallcaps}-Trp was a micromolar activator for all these enzymes with K~A~s in the range of 27--44 µM for hCA I and II, and with a K~A~ of 8.98 µM against mtCA 3 ([Table 1](#t0001){ref-type="table"}). [l]{.smallcaps}-Trp induced an increase of the kinetic constant of hCA I and II compared with the uncatalysed rate (of 1.7--3.5 times, which for such efficient enzymes is highly significant). For the mtCA 3, a similar kinetic effect was observed, with an increase of k~cat~ of 3.2 times in the presence of 10 µM [l]{.smallcaps}-Trp (compared with the rate in the absence of activator). We stress again, K~M~ remained the same in the presence and absence of activator, which proves that the substrate and activator binding sites are different (this has been confirmed by X-ray crystallography for several α-CAs complexed with activators)[@CIT0023].

###### 

Activation of human carbonic anhydrase (hCA) isozymes I, II and mtCA 3 with [l]{.smallcaps}-Trp, at 25 °C, for the CO~2~ hydration reaction[@CIT0034].

  Isozyme                                  k~cat~[^c^](#TF3){ref-type="table-fn"} (s^−1^)   K~M~[^c^](#TF3){ref-type="table-fn"} (mM)   (k~cat~)~[l]{.smallcaps}-Trp~^d^ (s^−1^)   K~A~^e^ (μM) [l]{.smallcaps}-Trp
  ---------------------------------------- ------------------------------------------------ ------------------------------------------- ------------------------------------------ ----------------------------------
  hCA I[^a^](#TF1){ref-type="table-fn"}    2.0 × 10^5^                                      4.0                                         3.4 × 10^5^                                44
  hCA II[^a^](#TF1){ref-type="table-fn"}   1.4 × 10^6^                                      9.3                                         4.9 × 10^6^                                27
  mtCA 3[^b^](#TF2){ref-type="table-fn"}   4.3 × 10^5^                                      10.7                                        13.8 × 10^5^                               8.98

Human recombinant isozymes, from Ref.[@CIT0023].

Bacterial recombinant enzyme, this work.

Observed catalytic rate without activator. K~M~ values in the presence and the absence of activators were the same for the various CAs (data not shown).

Observed catalytic rate in the presence of 10 μM activator.

The activation constant (K~A~) for each enzyme was obtained by fitting the observed catalytic enhancements as a function of the activator concentration.[@CIT0011] Mean from at least three determinations by a stopped-flow, CO~2~ hydrase method[@CIT0034]. Standard errors were in the range of 5--10% of the reported values (data not shown).

Amino acids and amines **1--19** ([Figure 1](#F0001){ref-type="fig"}) previously investigated as CAAs of human (α-class) CAs[@CIT0023] and for the activation of few bacterial enzymes[@CIT0033] showed significant activating effects against mtCA 3, as observed from data of [Table 2](#t0002){ref-type="table"}, in which the activation constants (K~A~s) of these compounds against three CAs are presented (hCA I and II data are included for comparison reasons)[@CIT0023]. The following structure-activity relationship (SAR) can be evidenced from the data of [Table 2](#t0002){ref-type="table"}:

###### 

Activation constants of hCA I, hCA II and the bacterial mtCA 3 with amino acids and amines **1--19**. Data for hCA I and II are from Ref.[@CIT0023].

                                         K~A~ (μM)[^c^](#TF8){ref-type="table-fn"}           
  -------- ----------------------------- ------------------------------------------- ------- ------
  **1**    [l]{.smallcaps}-His           0.03                                        10.9    18.2
  **2**    [d]{.smallcaps}-His           0.09                                        43      32.5
  **3**    [l]{.smallcaps}-Phe           0.07                                        0.013   30.6
  **4**    [d]{.smallcaps}-Phe           86                                          0.035   44.1
  **5**    [l]{.smallcaps}-DOPA          3.1                                         11.4    30.0
  **6**    [d]{.smallcaps}-DOPA          4.9                                         7.8     9.74
  **7**    [l]{.smallcaps}-Trp           44                                          27      8.98
  **8**    [d]{.smallcaps}-Trp           41                                          12      43.7
  **9**    [l]{.smallcaps}-Tyr           0.02                                        0.011   28.9
  **10**   [d]{.smallcaps}-Tyr           0.04                                        0.013   17.6
  **11**   4-H~2~N-L-Phe                 0.24                                        0.15    40.5
  **12**   Histamine                     2.1                                         125     34.2
  **13**   Dopamine                      13.5                                        9.2     12.1
  **14**   Serotonin                     45                                          50      10.3
  **15**   2-Pyridyl-methylamine         26                                          34      43.3
  **16**   2-(2-Aminoethyl)pyridine      13                                          15      45.9
  **17**   1-(2-Aminoethyl)-piperazine   7.4                                         2.3     50.3
  **18**   4-(2-Aminoethyl)-morpholine   0.14                                        0.19    52.0
  **19**   [l]{.smallcaps}-Adrenaline    0.09                                        96      52.2

Human recombinant isozymes, stopped flow CO~2~ hydrase assay method[@CIT0023].

This work.

Mean from three determinations by a stopped-flow, CO~2~ hydrase method[@CIT0034]. Standard errors were in the range of 5--10% of the reported values (data not shown).

i.  The most effective mtCA 3 activators were [d]{.smallcaps}-DOPA, [l]{.smallcaps}-Trp, dopamine and serotonin, with K~A~s ranging between 8.98 and 12.1 µM. Thus, both amino acid and amine types of activators show efficient activating effects on mtCA 3.

ii. [l]{.smallcaps}-His and [d]{.smallcaps}-Tyr showed medium potency activating effects, with K~A~s in the range of 17.6--18.2 µM.

iii. The remaining derivatives showed a weaker mtCA 3 activation potency, with K~A~s in the range of 28.9--52.2 µM. The SAR is thus rather well defined. For example, with few exceptions the [l]{.smallcaps}-amino acids were more effective mtCA 3 activators compared with the corresponding [d]{.smallcaps}-enantiomer. The exceptions are [d]{.smallcaps}-DOPA and [d]{.smallcaps}-Tyr which were more effective mtCA 3 activators compared with the corresponding [l]{.smallcaps}-enantiomer. Amines (with the exception of dopamine and serotonin) were generally less effective mtCA 3 activators compared with structurally related amino acid derivatives (compare histamine and [l]{.smallcaps}-/[d]{.smallcaps}-His; [l]{.smallcaps}-adrenaline and [l]{.smallcaps}-/[d]{.smallcaps}-DOPA, etc.), but the differences were not very important. In fact, no submicromolar mtCA 3 activators were detected in this study.

iv. There were important differences of activity for these CAAs against the human isoforms hCA I and II compared to the mycobacterial enzyme mtCA 3. Only [l]{.smallcaps}-Trp and serotonin were better activators of the bacterial versus the human isoforms, whereas all other compounds were more effective (sometimes in the nanomolar range) for activating the human CAs ([Table 2](#t0002){ref-type="table"}).

4.. Conclusions {#s0006}
===============

The first activation study of a mycobacterial CA is reported here. mtCA 3 was effectively activated by D-DOPA, [l]{.smallcaps}-Trp, dopamine and serotonin, with K~A~s ranging between 8.98 and 12.1 µM. [l]{.smallcaps}-His and [d]{.smallcaps}-Tyr showed medium potency activating effects, with K~A~s in the range of 17.6--18.2 µM, whereas other amines and amino acids were weakly effective activators, with K~A~s in the range of 28.9--52.2 µM. As the physiological role of the three mtCAs is poorly understood at this moment and the inhibition of such enzymes was shown to lead to strong antibacterial effects, modulating the activity of these CAs may lead to a better understanding of factors connected to the invasion and colonisation of the host during *Mycobacterium tuberculosis* infection.
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